Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis

Area of Science:

• Rheumatology
• Hepatology
• Virology

Background:

• Hepatitis C virus (HCV) is a hepato- and lymphotropic virus.
• HCV infection can induce various autoimmune rheumatic disorders, including vasculitis, sicca syndrome, arthralgias/arthritis, and fibromyalgia.
• The clinical severity of HCV-related rheumatic manifestations varies, sometimes posing life-threatening risks.

Purpose of the Study:

• To highlight the association between Hepatitis C virus and autoimmune rheumatic disorders.
• To emphasize the importance of differentiating HCV-related rheumatic conditions from primary rheumatic diseases.
• To discuss the therapeutic implications of new antiviral treatments in managing HCV-associated autoimmunity.

Main Methods:

• Review of clinical manifestations and associations between HCV infection and rheumatic disorders.
• Analysis of diagnostic challenges in distinguishing HCV-related autoimmunity from primary rheumatic diseases.
• Evaluation of treatment strategies, focusing on the impact of direct-acting antivirals versus interferon-based therapies.

Main Results:

• HCV infection can present with a spectrum of rheumatic symptoms that mimic primary autoimmune diseases.
• Accurate diagnosis is crucial as HCV-related rheumatic disorders require different management than primary conditions.
• Direct-acting antivirals (DAAs) represent a safer therapeutic approach compared to interferon-based therapies, reducing the risk of new or worsening autoimmune conditions.

Conclusions:

• Hepatitis C virus is a significant trigger for autoimmune rheumatic diseases.
• Distinguishing HCV-related rheumatic manifestations is critical for appropriate patient management and prognosis.
• Emerging direct-acting antiviral therapies offer a safer alternative for treating HCV, mitigating the risk of treatment-induced autoimmunity.